Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus Target Price from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.31.

A number of analysts have recently weighed in on TRVI shares. HC Wainwright raised their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th. B. Riley reissued a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Thursday, December 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, January 8th.

Trevi Therapeutics Stock Up 1.0 %

Trevi Therapeutics stock opened at $3.94 on Monday. Trevi Therapeutics has a 52-week low of $1.35 and a 52-week high of $4.68. The company has a market cap of $302.87 million, a price-to-earnings ratio of -8.95 and a beta of 0.87. The firm’s fifty day moving average is $3.67 and its 200 day moving average is $3.25.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the firm posted ($0.08) earnings per share. On average, equities research analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in shares of Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after acquiring an additional 117,418 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after buying an additional 69,167 shares in the last quarter. Barclays PLC lifted its stake in Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the period. State Street Corp lifted its position in shares of Trevi Therapeutics by 5.9% during the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after buying an additional 53,051 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.